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Human disease animal models are absolutely invaluable tools for our understanding of mechanisms involved in both physiological
and pathological processes. By studying various genetic abnormalities in these organisms we can get a better insight into potential
candidategenesresponsibleforhumandiseasedevelopment.Tothispointamouserepresentsoneofthemostusedandconvenient
species for human disease modeling. Hundreds if not thousands of inbred, congenic, and transgenic mouse models have been
created and are now extensively utilized in the research labs worldwide. Importantly, pluripotent stem cells play a signiﬁcant role
in developing new genetically engineered mice with the desired human disease-like phenotype. Induced pluripotent stem (iPS)
cells which represent reprogramming of somatic cells into pluripotent stem cells represent a signiﬁcant advancement in research
armament. The novel application of microRNA manipulation both in the generation of iPS cells and subsequent lineage-directed
diﬀerentiation is discussed. Potential applications of induced pluripotent stem cell—a relatively new type of pluripotent stem
cells—for human disease modeling by employing human iPS cells derived from normal and diseased somatic cells and iPS cells
derived from mouse models of human disease may lead to uncovering of disease mechanisms and novel therapies.
1.HumanDiseaseMouse Models
Model organisms such as fruit ﬂies, zebraﬁsh, and mice
have provided great insights into gene function in humans
because they are easy to grow and genetically manipulate in
the laboratory setting. By evaluating diﬀerent mutations in
theseorganisms,onecanidentifycandidategenesthatleadto
disease in humans and develop models to better understand
humandiseasepathogenesis[1].Themouseisanidealmodel
organism for human disease. Not only they are physiolog-
ically similar to humans, but a large genetic reservoir of
potential models of human disease has been accumulated
through the generation of radiation- or chemically induced
mutant loci. Multiple technological advances have dramati-
cally advanced our skills to create mouse models of human
diseases. High-resolution genetic and physical linkage maps
of the mouse genome have greatly facilitated the identiﬁ-
cation and cloning of mouse disease genes. Furthermore,
transgenic approaches allowed us to ectopically express or
make germline mutations in virtually any gene in the mouse
genome by using homologous recombination in embryonic
stem(ES)cells[2,3].Inbred,congenicandtransgenicstrains
are widely used in current research labs as very valuable tools
to investigate human diseases pathogenesis and develop new
eﬀective therapeutical strategies.
2. EmbryonicStem (ES)and Induced
PluripotentStem(iPS)Cells
Pluripotency is the ability of a cell to give rise to progeny
representing all types of cells in an organism [4]. Murine
embryonic stem cells derived from inner cell mass (ICM)
of the embryo exhibit two remarkable features in culture.
First, under certain conditions, they can be propagated
indeﬁnitely as a stable self-renewing population where every
cell undergoes symmetrical division. This immortalized
phenotype allows ES cells to be cultured over extended
periods of time. Upon diﬀerentiation, this feature is lost
and progeny undergoes cellular aging (Hayﬂick limit) as has2 Journal of Biomedicine and Biotechnology
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Figure 1: Generation of induced pluripotent stem cells from mouse model somatic cells.
been previously documented for all other nontransformed
primary cells [5]. A second feature is that, during culture,
ES cells retain their pluripotency and can diﬀerentiate into
the same range of cell types as those seen in the embryo
from ICM. The value of ES cells is partly due to their
amenability to extensive gene manipulation. Homologous
recombination between genomic and the exogenous DNA is
averyineﬃcientandrareprocess,butittakesplaceinEScells
withrelativelyhighereﬃciencythanitdoesinothercelltypes
[4].GenetargetingbyhomologousrecombinationinEScells
has improved our ability to study many biological processes
[3].SinceEScellscontributetoalltissuesuponinjectioninto
arecipientblastocyst,includingthegermline[6,7]modiﬁca-
tioninanEScellgenomecanbetransmitted,bythebreeding
of ES cell/wild-type chimaeras, to generate mice containing
the desired mutations in all cells. In this way mice with a
variety of modiﬁcations such as null and point mutations,
chromosomal rearrangements and large deletions have been
generated. In addition, it is possible to target reporter genes
under the control of speciﬁc promoters to study gene expres-
sion patterns in diﬀerent cell types. Furthermore, the ability
of ES cells to diﬀerentiate in vitro to many diﬀerent mature
somatic cell types, in combination with puriﬁcation of the
cell of interest by methods such as directed diﬀerentiation
and lineage selection, opens up the opportunity to use these
mature cell types for various basic and therapeutical applica-
tions [3]. Unfortunately, not every mouse model is permis-
sivefortrueEScellsderivation.Thismakesithardertoinves-
tigate gene function and pathogenesis in those strains. With
the advent of iPS technology this issue has been overcome.
In 2006, Takahashi and Yamanaka initially reported
the direct reprogramming of murine embryonic ﬁbroblasts
(MEFs) to pluripotent stem cells by introducing four
transcription factors [8]. Those factors, namely, Oct4, Sox2,
Klf4, andcMyc, thatareimportant forself-renewalofembry-
onic stem cells (ESCs) have been shown to reprogram both
mouse and human somatic cells into ESC-like pluripotent
cells (Figure 1). Since then, a large number of laboratories
have derived induced pluripotent stem cells from somatic
cells, and many important advances have been made [9–15].
Most importantly these iPS cells have shown properties very
similar to the ones of ES cells such as pluripotency markers
expression, teratoma formation, chimeras contribution, and
germline transmission. Moreover, the critical advantages of
iPS cells over ES cells now seem to be obvious. First of all iPS
cells are being generated from the autologous recipient thus
obviating the graft-versus-host problem in transplantation
settings. The second beneﬁt pertains to the ethical concerns.
Unlike in the past, one can now generate ES-like iPS cells
from human skin ﬁbroblasts or hair-follicle cells without
the need to resort to the human ES cell lines and potentially
(in the future) apply them to the therapeutic and/or basic
science approaches [13].
3. Making Use of iPS Cells for Human
DiseaseModeling
For the human disease animal modeling iPS cell technology
opened the way to even wider spectrum of available mouse
model strains. In 2009, Zhao et al. reported the generation of
all-iPS-derived viable, fertile live-born progeny by tetraploid
complementation [16] which further proved them to be
useful for the development of transgenic mice strains with
desired gene defects homologous to those seen in human
pathology.Journal of Biomedicine and Biotechnology 3
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Figure 2: Mouse induced pluripotent stem cells applications for human disease mouse modeling.
At present, with this valuable tool in hand one can take
literally any human disease mouse strain somatic cells (e.g.,
tail tip ﬁbroblasts) and induce pluripotent stem cells from
them. These disease-speciﬁc iPS cells can be further used
to explore given disease mechanisms both in vitro and in
vivo. (Figure 2). For example, human chronic lymphocytic
leukemia (CLL) (CD5+ B-cell malignancy) mouse model—
New Zealand Black mouse—exhibits a defect in the miR-
15a/16–1 gene on chromosome 14 which results in decreased
levels of these microRNAs, which is also seen in more than
50% of CLL patients [17]. Unfortunately, this mouse strain
is refractory to true ES cells derivation which makes it
diﬃcult to study the role of this microRNA gene defect in
B-cell development both in vitro and in vivo. In our lab, we
were able to successfully generate NZB iPS cells from spleen
stromal cells. Now they can be used as subjects for gene
targeting (correcting miR-15a/16–1 mutation and deletion)
followed by in vitro diﬀerentiation towards B-lineage. This
would help ﬁnd out what role this particular gene defect
plays in B-cell lymphogenesis and how its correction might
alleviate malignant clonal expansion. Furthermore, NZB iPS
cells with corrected miR-15a defect could be diﬀerentiated
into hematopoietic stem cells (HSCs) followed by their
adoptive transfer into appropriate recipients in order to
observe the eﬀect of gene correction on CLL development
in vivo.
Another way to utilize iPS cells to study human diseases
in animal models is xenograft transplantation assay. In this
case iPS cells would be generated from patient’s somatic
cells (Figure 3), diﬀerentiated into desired type of cells (e.g.,
HSC),andtransplantedintoimmunodeﬁcientmurinerecip-
ients. In a recent report, Yao et al. [18] have demonstrated
a generation of human iPS cells with zinc-ﬁnger nuclease,
mediated disruption of CCR5 locus which is known to be
a coreceptor for HIV entry. These patient-speciﬁc iPS cells
can now be diﬀerentiated into HSC and transplanted into
animal recipients to study the role of CCR5 in HIV infection
development in vivo. In another work, Lee et al. have used
human iPS-derived neural stem cells (NSCs) in a mouse
intracranial human glioma xenograft model [19]. In this
case, iPS-derived NSCs have been used as cellular vehicles
for targeted anticancer gene therapy since they will home
to the brain. As a proof of principle, Hanna and colleagues
have taken advantage of autologous iPS cells derived from
humanized mouse model of sickle cells anemia to correct
human sickle hemoglobin allele by gene-speciﬁc targeting
followed by their diﬀerentiation into hematopoietic stem
cells and transplantation into irradiated recipients [20]. It
has been shown that mice could be rescued from disease
progression after transplantation. This work has underlined
the beneﬁts of iPS technology for the combined gene and cell
therapy approach to study human disease in animal models.
It is needless to say that currently various labs worldwide
use patient-speciﬁc iPS cells for animal modeling both in
vitro and in vivo. Such pathological conditions as Hunting-
ton disease, amyotrophic lateral sclerosis, spinal muscular
dystrophy, Gaucher disease type III, Down syndrome, type 1
diabetes, Parkinson’s disease, β-thalassemia, and hepatic fail-
urehavebeeninvestigatedusingiPScellsgeneration[20–29].
4. MicroRNAs
MicroRNAs (miRs) are small noncoding RNAs which are
known to be critical for the expression control of more than
a third of all protein coding genes [30] by means of binding
to the 3 untranslated region (UTR) of target mRNAs via an
imperfect match to repress their translation and/or stability
[31]. They have been implicated in the regulation of many
biologicalprocesses,includingthestemcellsself-renewaland
pluripotency[32–34].MiRNAsaregeneratedfromprecursor
transcripts—primary miRNAs (pri-miRNAs)—that are ﬁrst
processed in the nucleus into an intermediate pre-miRNAs
by the complex of enzymes containing Drosha and DGCR8
proteins [35–37]. The pre-miRNAs are then transported
by the exportin 5-RanGTP shuttle into the cytoplasm, in
which they are further processed by Dicer, into mature
miRNAs [38]. In ES cells a set of microRNAs (including
miR-302 and miR-17–92 clusters) closely interfere with the4 Journal of Biomedicine and Biotechnology
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Figure 3: Human induced pluripotent stem cells applications for human disease mouse models.
key pluripotency factors such as Oct4, Sox2, and Nanog
[39, 40] thereby preventing them from diﬀerentiation and
controlling their proper self-renewal potential [41]. Xu et
al. have demonstrated miR-145 to control the expression of
Oct4, Sox2, and Klf4 and repress self-renewal of human ES
cells [42]. On the other hand, c-Myc has been reported to
repress miRNAs such as miR-21, let-7a, and miR-29a during
reprogramming [43]. Tissue-speciﬁc miRNAs often play
important roles in normal tissues and organ formation [44,
45]. More importantly for the current review, microRNAs
proved to be eﬀective tools for the iPS generation. In
particular, inhibition of miR-21, let-7a, or mir-29a has
been shown to enhance the reprogramming eﬃciency [43].
Alternatively, overexpression of the miR302/367 cluster has
been shown to rapidly and eﬃciently reprogram both mouse
and human somatic cells to iPS state without any exogenous
transcription factors delivery through Oct4 gene expression
activation and the suppression of Hdac2 [46]. MicroRNA
gene expression proﬁling in human ES cells revealed speciﬁc
miR-signatures of elevated expression of miR-302 cluster,
miR-200 family members as well as miR-520 cluster [47].
This might imply the possibility of them to be used as
tools to increase the eﬃciency of iPS generation without
any exogenous interventions into the genomic DNA of the
host cells and serve as additional iPS quality control markers.
Conversely, as the regulators of gene expression microRNAs
could be used to drive patient-speciﬁc iPS cells down the
speciﬁc cells lineage in vitro in order to produce the required
cell type to be studied [48].
Another promise that microRNAs are holding is the
development of microRNA-based gene targeting forthe tem-
poral gene-of-interest silencing [49]. For instance, aberrant
expression of Pax5 (also known as BSAP), a critical regulator
of B-cell development, is known to correlate with aggressive
subsets of B-cell non-Hodgkin lymphoma [50]. It has been
previously shown that overexpression of miR-15a/16 reduces
endogenous c-Myb levels and compromises Pax5 function
[51]. Now one can produce iPS cells from Pax5-aﬀected
non-Hodgkin lymphoma patient and apply in vitro B-cell
diﬀerentiation protocol along with miR-15a/16–1 delivery to
evaluate lymphomagenesis in the mouse xenograft model.
Potentially, the similar approach could be employed for the
discovery of leukemia (or more commonly cancer) stem
cells [52]. Finally, miRs can be used as biomarkers of
human disease progression in mouse model settings. Overall
diagram of microRNA application for mouse modeling is
shown in Figure 4.
5. Conclusion
The importance of disease mouse models and their impact
on medical research is hard to overestimate. Therefore
the value of animal modeling is very critical for our
understanding of human disease and development of new
eﬀective approaches to therapy. Induced pluripotent stem
cells hold a great promise for both basic and applied science
and open the road for many more opportunities for human
diseaseresearch.Coupledwiththeuseofﬁne-tuneregulatorsJournal of Biomedicine and Biotechnology 5
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Figure 4: MicroRNA applications for iPS-mediated human disease mouse models.
of gene expression, microRNAs, and mouse modeling they
have a promising potential for subsequent discoveries and
new therapies development in the complex ﬁeld of human
pathology.
References
[1] N. L. Washington, M. A. Haendel, C. J. Mungall, M. Ash-
burner, M. Westerﬁeld, and S. E. Lewis, “Linking human
diseases to animal models using ontology-based phenotype
annotation,” PLoS Biology, vol. 7, no. 11, Article ID e1000247,
2009.
[2] M. A. Bedell, N. A. Jenkins, and N. G. Copeland, “Mouse
models of human disease. Part I: techniques and resources for
genetic analysis in mice,” Genes and Development, vol. 11, no.
1, pp. 1–10, 1997.
[3] L. Hook, C. O’Brien, and T. Allsopp, “ES cell technology:
an introduction to genetic manipulation, diﬀerentiation and
therapeutic cloning,” Advanced Drug Delivery Reviews, vol. 57,
no. 13, pp. 1904–1917, 2005.
[4] H. Niwa, “Mouse ES cell culture system as a model of
development,” Development Growth and Diﬀerentiation, vol.
52, no. 3, pp. 275–283, 2010.
[5] S. Ohtsuka and S. Dalton, “Molecular and biological proper-
ties of pluripotent embryonic stem cells,” Gene Therapy, vol.
15, no. 2, pp. 74–81, 2008.
[ 6 ]A .B r a d l e y ,M .E v a n s ,M .H .K a u f m a n ,a n dE .R o b e r t s o n ,
“Formation of germ-line chimaeras from embryo-derived
teratocarcinomacelllines,”Nature,vol.309,no.5965,pp.255–
256, 1984.
[ 7 ]E .R o b e r t s o n ,A .B r a d l e y ,M .K u e h n ,a n dM .E v a n s ,“ G e r m -
line transmission of genes introduced into cultured pluripo-
tential cells by retroviral vector,” Nature, vol. 323, no. 6087,
pp. 445–448, 1986.
[8] K.TakahashiandS.Yamanaka,“Inductionofpluripotentstem
cells from mouse embryonic and adult ﬁbroblast cultures by
deﬁned factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006.
[9] K. Okita, M. Nakagawa, H. Hyenjong, T. Ichisaka, and S.
Yamanaka, “Generation of mouse induced pluripotent stem
cellswithoutviralvectors,”Science,vol.322,no.5903,pp.949–
953, 2008.
[10] M. Stadtfeld, M. Nagaya, J. Utikal, G. Weir, and K.
Hochedlinger, “Induced pluripotent stem cells generated
without viral integration,” Science, vol. 322, no. 5903, pp. 945–
949, 2008.
[11] T. Seki, S. Yuasa, M. Oda et al., “Generation of induced
pluripotent stem cells from human terminally diﬀerentiated
circulating T cells,” Cell stem cell, vol. 7, no. 1, pp. 11–14, 2010.
[12] M. Wernig, A. Meissner, R. Foreman et al., “In vitro repro-
gramming of ﬁbroblasts into a pluripotent ES-cell-like state,”
Nature, vol. 448, no. 7151, pp. 318–324, 2007.
[13] J. Zou, M. L. Maeder, P. Mali et al., “Gene Targeting of a
Disease-Related Gene in Human Induced Pluripotent Stem
and Embryonic Stem Cells,” Cell Stem Cell,v o l .5 ,n o .1 ,p p .
97–110, 2009.
[14] M. I. Lai, W. Y. Wendy-Yeo, R. Ramasamy et al., “Advance-
ments in reprogramming strategies for the generation of
induced pluripotent stem cells,” Journal of Assisted Reproduc-
tion and Genetics, vol. 28, no. 4, pp. 291–301, 2011.
[15] K. Takahashi, “Direct reprogramming 101,” Development
Growth and Diﬀerentiation, vol. 52, no. 3, pp. 319–333, 2010.6 Journal of Biomedicine and Biotechnology
[16] X. Y. Zhao, W. Li, Z. Lv et al., “IPS cells produce viable mice
through tetraploid complementation,” Nature, vol. 461, no.
7260, pp. 86–90, 2009.
[17] E. Salerno, B. J. Scaglione, F. D. Coﬀman et al., “Correcting
miR-15a/16 genetic defect in New Zealand Black mouse
model of CLL enhances drug sensitivity,” Molecular Cancer
Therapeutics, vol. 8, no. 9, pp. 2684–2692, 2009.
[18] Y. Yao, B. Nashun, T. Zhou et al., “Generation of CD34+
cells from CCR5-disrupted human embryonic and induced
pluripotent stem cells,” Human Gene Therapy, vol. 23, no. 2,
pp. 238–242, 2012.
[19] E. X. Lee, D. H. Lam, C. Wu et al., “Glioma gene therapy
using induced pluripotent stem cell derived neural stem cells,”
Molecular Pharmaceutics, vol. 8, no. 5, pp. 1515–1524, 2011.
[20] J. Hanna, M. Wernig, S. Markoulaki et al., “Treatment of
sickle cell anemia mouse model with iPS cells generated from
autologous skin,” Science, vol. 318, no. 5858, pp. 1920–1923,
2007.
[21] J. T. Dimos, K. T. Rodolfa, K. K. Niakan et al., “Induced
pluripotent stem cells generated from patients with ALS can
be diﬀerentiated into motor neurons,” Science, vol. 321, no.
5893, pp. 1218–1221, 2008.
[22] A. D. Ebert, J. Yu, F. F. Rose et al., “Induced pluripotent stem
cells from a spinal muscular atrophy patient,” Nature, vol. 457,
no. 7227, pp. 277–280, 2009.
[23] I. H. Park, N. Arora, H. Huo et al., “Disease-speciﬁc induced
pluripotentstemcells,” Cell,vol.134,no.5,pp.877–886, 2008.
[24] F.Soldner,D.Hockemeyer,C.Beardetal.,“Parkinson’sdisease
patient-derived induced pluripotent stem cells free of viral
reprogramming factors,” Cell, vol. 136, no. 5, pp. 964–977,
2009.
[25] L. Ye, J. C. Chang, C. Lin, X. Sun, J. Yu, and Y. W. Kan,
“Induced pluripotent stem cells oﬀer new approach to therapy
in thalassemia and sickle cell anemia and option in prenatal
diagnosis in genetic diseases,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 106,
no. 24, pp. 9826–9830, 2009.
[26] M. Wernig, J. P. Zhao, J. Pruszak et al., “Neurons derived from
reprogrammed ﬁbroblasts functionally integrate into the fetal
brainandimprovesymptomsofratswithParkinson’sdisease,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 105, no. 15, pp. 5856–5861, 2008.
[27] Q.Zhou,J.Brown,A.Kanarek,J.Rajagopal, andD.A.Melton,
“In vivo reprogramming of adult pancreatic exocrine cells to
β-cells,” Nature, vol. 455, no. 7213, pp. 627–632, 2008.
[28] I. S. Behbahan, Y. Duan, A. Lam et al., “New approaches in the
diﬀerentiation of human embryonic stem cells and induced
pluripotent stem cells toward hepatocytes,” Stem Cell Reviews
and Reports, vol. 7, no. 3, pp. 748–759, 2011.
[29] S. Asgari, M. Moslem, K. Bagheri-Lankarani, B. Pournasr,
M. Miryounesi, and H. Baharvand, “Diﬀerentiation and
transplantation of human induced pluripotent stem cell-
derived hepatocyte-like cells,” Stem Cell Reviews and Reports.
In press.
[30] S. K. Mallanna and A. Rizzino, “Emerging roles of microRNAs
in the control of embryonic stem cells and the generation of
induced pluripotent stem cells,” Developmental Biology, vol.
344, no. 1, pp. 16–25, 2010.
[31] T. M. Rana, “Illuminating the silence: understanding the
structure and function of small RNAs,” Nature Reviews
Molecular Cell Biology, vol. 8, no. 1, pp. 23–36, 2007.
[32] C. Melton, R. L. Judson, and R. Blelloch, “Opposing
microRNA families regulate self-renewal in mouse embryonic
stem cells,” Nature, vol. 463, no. 7281, pp. 621–626, 2010.
[33] Y. Tay, J. Zhang, A. M. Thomson, B. Lim, and I. Rigoutsos,
“MicroRNAs to Nanog, Oct4 and Sox2 coding regions modu-
late embryonic stem cell diﬀerentiation,” Nature, vol. 455, no.
7216, pp. 1124–1128, 2008.
[34] Y. M. S. Tay, W. L. Tam, Y. S. Ang et al., “MicroRNA-134
modulates the diﬀerentiation of mouse embryonic stem cells,
where it causes post-transcriptional attenuation of Nanog and
LRH1,” Stem Cells, vol. 26, no. 1, pp. 17–29, 2008.
[35] Y. Lee, C. Ahn, J. Han et al., “The nuclear RNase III Drosha
initiatesmicroRNAprocessing,”Nature,vol.425,no.6956,pp.
415–419, 2003.
[ 3 6 ]Y .L e e ,K .J e o n ,J .T .L e e ,S .K i m ,a n dV .N .K i m ,“ M i c r o R N A
maturation: stepwise processing and subcellular localization,”
EMBO Journal, vol. 21, no. 17, pp. 4663–4670, 2002.
[37] Y. Zeng and B. R. Cullen, “Sequence requirements for micro
RNA processing and function in human cells,” RNA, vol. 9,
no. 1, pp. 112–123, 2003.
[38] V. K. Gangaraju and H. Lin, “MicroRNAs: key regulators of
stem cells,” Nature Reviews Molecular Cell Biology, vol. 10, no.
2, pp. 116–125, 2009.
[39] A. Marson, S. S. Levine, M. F. Cole et al., “Connecting
microRNA genes to the core transcriptional regulatory cir-
cuitry of embryonic stem cells,” Cell, vol. 134, no. 3, pp. 521–
533, 2008.
[ 4 0 ]K .D .W i l s o n ,S .V e n k a t a s u b r a h m a n y a m ,F .J i a ,N .S u n ,A .J .
Butte, and J. C. Wu, “MicroRNA proﬁling of human-induced
pluripotent stem cells,” Stem Cells and Development, vol. 18,
no. 5, pp. 749–757, 2009.
[41] Y. Wang, R. Medvid, C. Melton, R. Jaenisch, and R. Blelloch,
“DGCR8isessentialformicroRNAbiogenesisandsilencingof
embryonicstemcell self-renewal,” Nature Genetics,vol.39,no.
3, pp. 380–385, 2007.
[ 4 2 ] N .X u ,T .P a p a g i a n n a k o p o u l o s ,G .P a n ,J .A .T h o m s o n ,a n dK .
S. Kosik, “MicroRNA-145 regulates OCT4, SOX2, and KLF4
and represses pluripotency in human embryonic stem cells,”
Cell, vol. 137, no. 4, pp. 647–658, 2009.
[43] C. S. Yang, Z. Li, and T. M. Rana, “microRNAs modulate iPS
cell generation,” RNA, vol. 17, no. 8, pp. 1451–1460, 2011.
[44] K. N. Ivey, A. Muth, J. Arnold et al., “MicroRNA regulation of
cell lineages in mouse and human embryonic stem cells,” Cell
Stem Cell, vol. 2, no. 3, pp. 219–229, 2008.
[45] Y. Zhao, E. Samal, and D. Srivastava, “Serum response factor
regulates a muscle-speciﬁc microRNA that targets Hand2
during cardiogenesis,” Nature, vol. 436, no. 7048, pp. 214–220,
2005.
[46] F. Anokye-Danso, C. M. Trivedi, D. Juhr et al., “Highly
eﬃcient miRNA-mediated reprogramming of mouse and
human somatic cells to pluripotency,” Cell Stem Cell, vol. 8,
no. 4, pp. 376–388, 2011.
[47] J. Ren, P. Jin, E. Wang, F. M. Marincola, and D. F. Stroncek,
“MicroRNA and gene expression patterns in the diﬀerentia-
tion of human embryonic stem cells,” Journal of Translational
Medicine, vol. 7, article 20, 2009.
[48] L. R. Saunders et al., “miRNAs regulate SIRT1 expression
duringmouseembryonicstemcelldiﬀerentiationandinadult
mouse tissues,” Aging, vol. 2, no. 7, pp. 415–431, 2010.
[49] C. C. Lan, I. U. S. Leong, D. Lai, and D. R. Love, “Disease
modeling by gene targeting using MicroRNAs,” Methods in
Cell Biology, vol. 105, pp. 419–436, 2011.
[50] L. Krenacs, A. W. Himmelmann, L. Quintanilla-Martinez
et al., “Transcription factor B-cell-speciﬁc activator protein
(BSAP) is diﬀerentially expressed in B cells and in subsets of
B-cell lymphomas,” Blood, vol. 92, no. 4, pp. 1308–1316, 1998.Journal of Biomedicine and Biotechnology 7
[51] E. Y. Chung, M. Dews, D. Cozma et al., “c-Myb oncoprotein
is an essential target of the dleu2 tumor suppressor microRNA
cluster,” Cancer Biology and Therapy, vol. 7, no. 11, pp. 1758–
1764, 2008.
[52] P. H. Gunaratne, “Embryonic stem cell MicroRNAs: deﬁning
factors in induced pluripotent (iPS) and cancer (CSC) stem
cells?” C u r r e n tS t e mC e l lR e s e a r c ha n dT h e r a p y ,v o l .4 ,n o .3 ,
pp. 168–177, 2009.